Furthermore, the combination of nivolumab and chemotherapy in the first-line treatment of PD-L1 CPS ≥ 5 GEJ cancer/gastric cancer patients also showed a pronounced benefit in OS in the MSI-high subgroup (HR 0.33, 09% CI; CHECKMATE-649 trial) [22]. Here, CD274 is linked to gastric cancer.